| Name | AG-1478 |
| Description | AG-1478 (NSC-693255) (Tyrphostin AG-1478) is a selective EGFR inhibitor. |
| Cell Research | Cells are exposed to different concentrations of AG-1478 for 72 hours in 96-well plates. The effects of AG-1478 on cell growth are examined using an Alamar Blue assay. A 20-μL aliquot of Alamar Blue is added to each well, and its absorbance is determined using a Spectromax Scanning Micro plate Reader. The effects of AG-1478 are expressed as percentage of growth inhibition using untreated cells as the control (0% inhibition). Cellular DNA synthesis is determined using a [3H]thymidine incorporation assay. (Only for Reference) |
| In vitro | Co-administration of 0.4 mg AG-1478 with a single dose of 25 μCi 90Y-CHX-A''-DTPA-hu3S193 results in significantly enhanced potency compared to the drugs administered separately. AG-1478 blocks phosphorylation of EGFR at tumor sites and inhibits growth in xenograft models of A431 cells overexpressing wt EGFR and glioma expressing de2-7 EGFR. Even subtherapeutic doses of AG-1478 significantly increase the potency of cytotoxic drugs. The combination of AG-1478 and temozolomide shows synergistic antitumor activity against human glioma xenografts. |
| In vivo | At a concentration of 0.25 μM, AG-1478 effectively inhibits Ang II, Ca2+ ionophore, and EGF-induced MAPK activation in VSMCs, without affecting fosinopril or platelet-derived growth factor-BB (PDGF-BB)-induced MAPK activation. AG-1478 also suppresses EGF-induced mitosis in BaF/ERX and LIM1215 cells, with IC50 values of 0.07 μM and 0.2 μM, respectively. Furthermore, AG-1478 inhibits the function of ABC (ATP-binding cassette) transport proteins, such as ABCB1 and ABCG2, showing a more significant effect on ABCG2. In comparison to cells expressing endogenous wild-type EGFR or overexpressing exogenous wild-type EGFR (with IC50 values of 34.6 μM and 48.4 μM respectively), AG-1478 preferentially inhibits U87 mg cells expressing ΔEGFR, with an IC50 of 8.7 μM. It also preferentially inhibits tyrosine kinase activity and autophosphorylation of ΔEGFR over endogenous or overexpressed exogenous wild-type EGFR. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 4.23 mg/mL (13.4 mM), Sonication is recommended.
|
| Keywords | diseases | encephalomyocarditis | HCV | virus | HER1 | obesity | EGFR | cardiovascular | Influenza Virus | myocardial | injury | ErbB-1 | EMCV | Hepatitis C virus | antiviral | AG 1478 | NSC693255 | Tyrphostin AG 1478 | Epidermal growth factor receptor | inhibit | Inhibitor | cancer | NSC-693255 | chemotherapy | AG-1478 | Tyrphostin AG1478 |
| Inhibitors Related | Rifampicin | Acetylcysteine | α-Vitamin E | Sorafenib | Nitazoxanide | Curcumin | Artemisinin | Naringenin | Gefitinib | Salcomine | Crystal Violet | Pazopanib |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Breast Cancer Compound Library | Anti-Viral Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library |
United States
